MedTrace Logo

Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy

NCT00791570 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2012-10-16

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and time to progression of HLA-A\*2402 or A\*0201 restricted epitope peptides VEGFR1 and VEGFR2 emulsified with Montanide ISA 51 in patients with Neovascular Maculopathy, including Age Related Macular Degeneration

Conditions

  • Neovascular Maculopathy
  • Age Related Macular Degeneration

Interventions

BIOLOGICAL

VEGFR1 and VEGFR2

Biological: VEGFR1 and VEGFR2 Patients will be vaccinated once a week for 12 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.

Sponsors & Collaborators

  • Human Genome Center, Institute of Medical Science, University of Tokyo

    collaborator OTHER

  • Osaka University

    lead OTHER

Principal Investigators

  • Kohji Nishida, MD, PhD · Chair of Ophthalmology, Osaka University Medical School

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00791570 on ClinicalTrials.gov